A complete Texas research reference for tirzepatide — dual GIP/GLP-1 receptor agonism, published study data, and analytical documentation expectations.
Written for the Texas research community, this reference brings together the documentation Texas peptide research labs need on tirzepatide that labs from Austin to Houston, Dallas to San Antonio typically request when qualifying a new lot. Every batch we dispatch from our Texas warehouse ships with the analytical documentation described below.
Tirzepatide is a once-weekly synthetic peptide that engages both the GIP and GLP-1 incretin receptors. In Texas research programs — from metabolic-disease labs in the Houston medical corridor to endocrine research groups at UT Austin — it has become one of the most heavily characterized incretin agonists on the bench.
What is tirzepatide?
Tirzepatide is a 39-amino-acid linear peptide engineered from the native GIP backbone with substitutions that confer dual receptor agonism and resistance to DPP-4 cleavage. A C20 fatty diacid moiety extends plasma half-life via reversible albumin binding, supporting the once-weekly research administration interval seen in published protocols.
Mechanism of action
- Dual agonism at the GIP and GLP-1 receptors — both class B GPCRs.
- Sustained albumin binding extends circulating half-life to roughly 5 days in published pharmacokinetic studies.
- DPP-4-resistant backbone modification preserves bioactive structure across the dosing interval.
- Downstream cAMP signaling supports the glucose- and weight-related endpoints reported in SURPASS and SURMOUNT publications.
Tirzepatide research dosage reference
Published clinical literature most commonly references the following weekly tirzepatide titration schedule. This is provided strictly as a literature reference, not as guidance for use.
| Week | Reference Weekly Dose | Phase |
|---|---|---|
| 1–4 | 2.5 mg | Initiation |
| 5–8 | 5 mg | Titration |
| 9–12 | 7.5 mg | Titration |
| 13–16 | 10 mg | Maintenance |
| 17–20 | 12.5 mg | Maintenance |
| 21+ | 15 mg | Maintenance (max published) |
Reconstitution and stability
Lyophilized tirzepatide is typically reconstituted with bacteriostatic water for laboratory work. Reconstituted material is generally documented as stable for up to 30 days at 2–8°C; lyophilized powder is documented as stable at -20°C for 24+ months when shipped in the insulated packaging used from our Texas dispatch center.
What a complete tirzepatide COA shows
- Batch identifier and synthesis date
- HPLC purity (≥98% for research-grade material)
- LC-MS confirmed exact mass (~4813.45 Da monoisotopic)
- Acetate or trifluoroacetate counterion content
- Bacterial endotoxin and residual solvents per analytical method
What is the molecular weight of tirzepatide?
Approximately 4813.45 Da, confirmed by LC-MS on every research-grade batch.
How is tirzepatide stored before reconstitution?
Lyophilized tirzepatide is stored at -20°C, protected from light and moisture, and used within published shelf life.
Is tirzepatide the same as semaglutide?
No. Semaglutide is a GLP-1 mono-agonist; tirzepatide is a dual GIP/GLP-1 agonist with a different backbone, mass, and pharmacology.
Pep Labs 365 ships every research peptide from our Texas facility with a lot-matched Certificate of Analysis, third-party HPLC purity, and LC-MS identity confirmation.
